



Image

1631
#

Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 22nd day of March 2004.

(s) Linda S. Evans
Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Luukkonen et al.	Atty. Docket: PRI-0019 (ORT-1461)
Serial No.:	09/921,512	Art Unit: 1631
Filed:	August 1, 2001	Examiner: Carolyn L. Smith
For:	Gene Expression Profile For KSHV Infection And Methods For Treating Same	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statements dated February 4, 2002, and December 12, 2001, filed in the above-identified application. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing additional references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(c). The required statement as specified at 37 C.F.R. § 1.97(e) follows.

The references listed on the enclosed form were first cited in a counterpart European application in a Supplementary Partial European Search Report not more than three months prior to the filing of this Statement. A copy of the Supplementary Partial European Search Report is enclosed.

A copy of each reference listed on the enclosed Form PTO-1449 is enclosed. Each reference is in the English language.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that the cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information and more material does not exist.

The Examiner is respectfully requested to initial the citation on the Form PTO-1449 to confirm consideration of the references.

If any fees are due in connection with the filing of this Statement, including the fee set forth in 37 C.F.R. § 1.17(p) in the event an action closing prosecution has been mailed, please charge all such required fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date: March 22, 2004


Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406



1651
#

Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 22nd day of March 2004.

(s)

Linda S. Evans
Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Luukkonen et al.	Atty. Docket:	PRI-0019 (ORT-1461)
Serial No.:	09/921,512	Art Unit:	1631
Filed:	August 1, 2001	Examiner:	Carolyn L. Smith
For:	Gene Expression Profile For KSHV Infection And Methods For Treating Same		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statements dated February 4, 2002, and December 12, 2001, filed in the above-identified application. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing additional references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(c). The required statement as specified at 37 C.F.R. § 1.97(e) follows.

The references listed on the enclosed form were first cited in a counterpart European application in a Supplementary Partial European Search Report not more than three months prior to the filing of this Statement. A copy of the Supplementary Partial European Search Report is enclosed.

A copy of each reference listed on the enclosed Form PTO-1449 is enclosed. Each reference is in the English language.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that the cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information and more material does not exist.

The Examiner is respectfully requested to initial the citation on the Form PTO-1449 to confirm consideration of the references.


If any fees are due in connection with the filing of this Statement, including the fee set forth in 37 C.F.R. § 1.17(p) in the event an action closing prosecution has been mailed, please charge all such required fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date: March 22, 2004


Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

PRI-0019 (ORT-1461)

09/921,512

**INFORMATION DISCLOSURE
CITATION BY APPLICANT**

(Use several sheets if necessary)

APPLICANT

Luukkonen et al.

FILING DATE

August 1, 2001

GROUP ART UNIT

1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Carlisle et al., "Development Of A Prostate cDNA Microarray And Statistical Gene Expression Analysis Package," <i>Molecular Carcinogenesis</i> , Vol. 28, pp. 12-22 (2000).
	Feigal, "AIDS-Associated Malignancies: Research Perspectives," <i>Biochimica et Biophysica Acta</i> , Vol. 1423, pp. C1-C9 (1998).
	Geiss et al., "Large-Scale Monitoring Of Host Cell Gene Expression During HIV-1 Infection Using cDNA Microarrays," <i>Virology</i> , Vol. 266, pp. 8-16 (2000).
	Kannan et al., "Profile Of Gene Expression Regulated By Induced p53: Connection To The TGF- β Family," <i>FEBS Letters</i> , Vol. 470, pp. 77-82 (2000).
	Jenner et al., "Kaposi's Sarcoma-Associated Herpesvirus Latent And Lytic Gene Expression As Revealed By DNA Arrays," <i>Journal Of Virology</i> , Vol. 75(2), pp. 891-902 (2001).
	Moses et al., "A Functional Genomics Approach To Kaposi's Sarcoma," <i>Annals Of The New York Academy Of Sciences</i> , Vol. 975, pp. 180-191 (2002).
	Moses et al., "Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation Of The c-kit Proto-Oncogene, As Identified By Gene Expression Profiling, Is Essential For The Transformation Of Endothelial Cells," <i>Journal of Virology</i> , Vol. 76(16), pp. 8383-8399 (2002).
	Nasti et al., "A Risk And Benefit Assessment Of Treatment For AIDS-Related Kaposi's Sarcoma," <i>Drug Safety</i> , Vol. 20(5), pp. 403-425 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.